A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study (Q35180428)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

7 August 2017

gynecologic oncology

1 reference

based on heuristic

inferred from title

Roisin E. O'Cearbhaill

4

object named as

Roisin E O'Cearbhaill

1 reference

Europe PubMed Central

7 August 2017

author name string

Susana M Campos

1

1 reference

Europe PubMed Central

7 August 2017

William E Brady

2

1 reference

Europe PubMed Central

7 August 2017

Katherine M Moxley

3

1 reference

Europe PubMed Central

7 August 2017

Paula S Lee

5

1 reference

Europe PubMed Central

7 August 2017

Paul A DiSilvestro

6

1 reference

Europe PubMed Central

7 August 2017

Jacob Rotmensch

7

1 reference

Europe PubMed Central

7 August 2017

Peter G Rose

8

1 reference

Europe PubMed Central

7 August 2017

Premal H Thaker

9

1 reference

Europe PubMed Central

7 August 2017

David M O'Malley

10

1 reference

Europe PubMed Central

7 August 2017

Parviz Hanjani

11

1 reference

Europe PubMed Central

7 August 2017

Rosemary E Zuna

12

1 reference

Europe PubMed Central

7 August 2017

Martee L Hensley

13

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

1 March 2014

1 reference

Europe PubMed Central

7 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

7 August 2017

133

1 reference

Europe PubMed Central

7 August 2017

3

1 reference

Europe PubMed Central

7 August 2017

537-541

1 reference

Europe PubMed Central

7 August 2017

Integrated genomic characterization of endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Prognostic significance of tumor angiogenesis in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Malignant mixed müllerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

Two cell lines established from mixed Müllerian tumors of the uterus morphologic, immunocytochemical, and cytogenetic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

13 July 2018

mTOR signaling, function, novel inhibitors, and therapeutic targets.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

Expression of various antigens by different components of uterine mixed müllerian tumors. An immunohistochemical study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

The Immunohistochemical Profile of Malignant Mixed Mullerian Tumor: Overlap with Endometrial Adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

27 September 2018

Phosphorylated KDR expression in endometrial cancer cells relates to HIF1α/VEGF pathway and unfavourable prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4360988

15 November 2018

Genomic aberrations in carcinomas of the uterine corpus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.036

7 January 2021

Malignant mixed Müllerian tumors of the uterus. An immunohistochemical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24594074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24594074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab therapy in patients with recurrent uterine neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/24594074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2014.02.036

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35180428&oldid=2035160361"